Company / Operating Cash Flow
INOVIO PHARMACEUTICALS, INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$104.1M
FY2025
5-year range
-$215.7M / -$97.9M
FY2021-FY2025
Trend
+16.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$216M to -$104M over the past 2 years.
Based on SEC 10-K filings.
-$104M in FY2025.
Improved from -$216M to -$104M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 16.3% year-over-year.
- Peak operating cash flow was recorded in FY2017.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$104.1M | +16.3% |
| FY2024 | -$124.4M | +42.3% |
| FY2023 | -$215.7M | -21.2% |
| FY2022 | -$178.0M | -81.9% |
| FY2021 | -$97.9M | -33.0% |
| FY2020 | -$73.6M | -16.4% |
| FY2019 | -$63.2M | -1.0% |
| FY2018 | -$62.6M | -402.9% |
| FY2017 | -$12.4M | +58.3% |
| FY2016 | -$29.8M | -93.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026